Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A.

Dyrk1A (dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 1A) is a serine/threonine kinase essential for brain development and function, and its excessive activity is considered a pathogenic factor in Down syndrome. The development of potent, selective inhibitors of Dyrk1A would help to elucidate the molecular mechanisms of normal and diseased brains, and may provide a new lead compound for molecular-targeted drug discovery. Here, we report a novel Dyrk1A inhibitor, INDY, a benzothiazole derivative showing a potent ATP-competitive inhibitory effect with IC(50) and K(i) values of 0.24 and 0.18 μM, respectively. X-ray crystallography of the Dyrk1A/INDY complex revealed the binding of INDY in the ATP pocket of the enzyme. INDY effectively reversed the aberrant tau-phosphorylation and rescued the repressed NFAT (nuclear factor of activated T cell) signalling induced by Dyrk1A overexpression. Importantly, proINDY, a prodrug of INDY, effectively recovered Xenopus embryos from head malformation induced by Dyrk1A overexpression, resulting in normally developed embryos and demonstrating the utility of proINDY in vivo.

[1]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[2]  G. Elston,et al.  Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/− mouse , 2005, Neurobiology of Disease.

[3]  A. Barthel,et al.  Alternative splicing variants of dual specificity tyrosine phosphorylated and regulated kinase 1B exhibit distinct patterns of expression and functional properties. , 2003, The Biochemical journal.

[4]  Philip R. Cohen,et al.  The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase. , 2001, The Biochemical journal.

[5]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[6]  木村 亮.  The DYRK1A gene, encoded in chromosome 21 down syndrome critical region, bridges between β-amyloid production and tau phosphorylation in Alzheimer disease , 2007 .

[7]  Y. Hérault,et al.  DYRK1A, a Novel Determinant of the Methionine-Homocysteine Cycle in Different Mouse Models Overexpressing this Down-Syndrome-Associated Kinase , 2009, PloS one.

[8]  Jan-Fang Cheng,et al.  Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome , 1997, Nature Genetics.

[9]  J. Wegiel,et al.  Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome , 2007, Neuroscience Letters.

[10]  T. Blundell,et al.  Identification of the autophosphorylation sites and characterization of their effects in the protein kinase DYRK1A. , 2001, The Biochemical journal.

[11]  X. Estivill,et al.  A human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region. , 1996, Human molecular genetics.

[12]  V. Longo,et al.  An investigation on the central effects of harmine, harmaline and related beta-carbolines. , 1971, Neuropharmacology.

[13]  M. Gerstein,et al.  The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies , 2009, Proceedings of the National Academy of Sciences.

[14]  E. Yamashita,et al.  Structure of human monoamine oxidase A at 2.2-Å resolution: The control of opening the entry for substrates/inhibitors , 2008, Proceedings of the National Academy of Sciences.

[15]  Hyun-Jeong Cho,et al.  DYRK1A-mediated Hyperphosphorylation of Tau , 2007, Journal of Biological Chemistry.

[16]  F. Rizzi,et al.  Molecular targets of (-)-epigallocatechin-3-gallate (EGCG): specificity and interaction with membrane lipid rafts. , 2008, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[17]  W. Becker,et al.  Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation , 2009, The FEBS journal.

[18]  Y. Gwack,et al.  A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT , 2006, Nature.

[19]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[20]  K. Johnson.  An Update. , 1984, Journal of food protection.

[21]  J. Wegiel,et al.  The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome , 2008, Acta Neuropathologica.

[22]  M. Dierssen,et al.  Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome , 2008, Neurobiology of Disease.

[23]  Xin Gao,et al.  NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21 , 2006, Nature.

[24]  A. Brunger.  Version 1.2 of the Crystallography and NMR system , 2007, Nature Protocols.

[25]  Hey-kyeong Jeong,et al.  DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects , 2006, Neurobiology of Disease.

[26]  H. Joost,et al.  Sequence Characteristics, Subcellular Localization, and Substrate Specificity of DYRK-related Kinases, a Novel Family of Dual Specificity Protein Kinases* , 1998, The Journal of Biological Chemistry.

[27]  Elizabeth M.C. Fisher,et al.  Down syndrome—recent progress and future prospects , 2009, Human molecular genetics.

[28]  Desmond J. Smith,et al.  Increased Dosage of DYRK1A and Brain Volumetric Alterations in a YAC Model of Partial Trisomy 21 , 2008, Anatomical record.

[29]  M. Pletnikov,et al.  Trisomy for the Down syndrome 'critical region' is necessary but not sufficient for brain phenotypes of trisomic mice. , 2007, Human molecular genetics.

[30]  T. Misteli,et al.  Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). , 2009, Bioorganic & medicinal chemistry letters.

[31]  Arif Demirdaş,et al.  Kaplan Sadock Comprehensive Textbook of Psychiatry , 2007 .

[32]  H. Wiśniewski,et al.  Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome , 1985, Annals of neurology.

[33]  K. Gardiner.  Molecular basis of pharmacotherapies for cognition in Down syndrome. , 2010, Trends in pharmacological sciences.

[34]  X. Estivill,et al.  Human minibrain homologue (MNBH/DYRK1): characterization, alternative splicing, differential tissue expression, and overexpression in Down syndrome. , 1999, Genomics.

[35]  Elizabeth J. Goldsmith,et al.  Activation Mechanism of the MAP Kinase ERK2 by Dual Phosphorylation , 1997, Cell.

[36]  George Stoica,et al.  A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. , 2010, Human molecular genetics.

[37]  T. Glover,et al.  Isolation of human and murine homologues of the Drosophila minibrain gene: human homologue maps to 21q22.2 in the Down syndrome "critical region". , 1996, Genomics.

[38]  Hiroshi Kimura,et al.  Manipulation of Alternative Splicing by a Newly Developed Inhibitor of Clks* , 2004, Journal of Biological Chemistry.

[39]  S. Mandel,et al.  Simultaneous Manipulation of Multiple Brain Targets by Green Tea Catechins: A Potential Neuroprotective Strategy for Alzheimer and Parkinson Diseases , 2008, CNS neuroscience & therapeutics.

[40]  X. Estivill,et al.  Motor phenotypic alterations in TgDyrk1a transgenic mice implicate DYRK1A in Down syndrome motor dysfunction , 2004, Neurobiology of Disease.

[41]  X. Estivill,et al.  Haploinsufficiency of Dyrk1A in mice leads to specific alterations in the development and regulation of motor activity. , 2004, Behavioral neuroscience.

[42]  N. Shimizu,et al.  Cloning of a human homolog of the Drosophila minibrain/rat Dyrk gene from "the Down syndrome critical region" of chromosome 21. , 1996, Biochemical and biophysical research communications.

[43]  T. Uema,et al.  The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease. , 2007, Human molecular genetics.

[44]  J. Wegiel,et al.  Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  M. Dierssen,et al.  Impaired Spatial Learning Strategies and Novel Object Recognition in Mice Haploinsufficient for the Dual Specificity Tyrosine-Regulated Kinase-1A (Dyrk1A) , 2008, PloS one.

[46]  H. Shibuya,et al.  Nemo-Like Kinase-Myocyte Enhancer Factor 2A Signaling Regulates Anterior Formation in Xenopus Development , 2007, Molecular and Cellular Biology.

[47]  Desmond J. Smith,et al.  Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A , 2009, PloS one.

[48]  G. Crabtree,et al.  NFAT Signaling Choreographing the Social Lives of Cells , 2002, Cell.

[49]  X. Estivill,et al.  Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome. , 2001, Human molecular genetics.

[50]  J. Delabar,et al.  The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development. , 2008, Developmental cell.

[51]  C. Epstein,et al.  The challenge of Down syndrome. , 2006, Trends in molecular medicine.

[52]  M. Hagiwara,et al.  Utilization of host SR protein kinases and RNA-splicing machinery during viral replication. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Naoto Ueno,et al.  Involvement of NLK and Sox11 in neural induction in Xenopus development , 2002, Genes to cells : devoted to molecular & cellular mechanisms.

[54]  R. Ramsay,et al.  Inhibition of Monoamine Oxidase A by β-Carboline Derivatives , 1997 .

[55]  X. Estivill,et al.  Cloning and characterization of DYRK1B, a novel member of the DYRK family of protein kinases. , 1999, Biochemical and biophysical research communications.

[56]  Lora J. H. Bean,et al.  Epidemiology of Down syndrome. , 2007, Mental retardation and developmental disabilities research reviews.

[57]  E. Rubin,et al.  Transgenic Mouse In Vivo Library of Human Down Syndrome Critical Region 1: Association between DYRK1A Overexpression, Brain Development Abnormalities, and Cell Cycle Protein Alteration , 2004, Journal of neuropathology and experimental neurology.

[58]  I. Ferrer,et al.  Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models , 2005, Neurobiology of Disease.

[59]  I. Graef,et al.  Calcineurin/NFAT Signaling Is Required for Neuregulin-Regulated Schwann Cell Differentiation , 2009, Science.

[60]  X. Estivill,et al.  Dyrk1A Haploinsufficiency Affects Viability and Causes Developmental Delay and Abnormal Brain Morphology in Mice , 2002, Molecular and Cellular Biology.